Colorectal Cancer | Topics

 
Transarterial Yttrium-90 Radioembolization Plus Second-Line Chemo Yield Longer PFS In Colorectal Liver Metastases
October 12, 2021

Patients with colorectal liver metastases who were treated with transarterial Yttrium-90 radioembolization plus second-line chemotherapy experienced a long-term survival benefit.

Presentation: ctDNA Assays For Patients With CRC Undergoing Resection of Metastases
October 08, 2021

Drs Liliana Bustamante and Richard Kim review “Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases,” by Loupakis F, et al.

Evidence Indicates That Active Monitoring Is a Viable Alternative to Maintenance Therapy in Stable or Responding Metastatic CRC
October 04, 2021

Investigators believe that active monitoring presents an alternative option to capecitabine maintenance therapy for patients with stable or responding metastatic colorectal cancer.

FDA Expands Label for Cetuximab Plus Encorafenib for BRAF V600E+ Metastatic Colorectal Cancer Following Prior Therapy
September 29, 2021

The FDA has expanded the label for cetuximab/encorafenib for the treatment of patients with previously treated BRAF V600E–positive metastatic colorectal cancer.

HER2 Expression Level Associated With Antitumor Activity of Trastuzumab Deruxtecan for HER2-Positive mCRC
September 22, 2021

An association was seen between baseline HER2 expression levels and the antitumor activity of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive, metastatic colorectal cancer.

The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer—From “MAYBE” to “MUST BE”
September 22, 2021

Takayuki Yoshino, MD, PhD provides perspective on key issues surrounding therapy selection in gastrointestinal cancers.

Adavosertib for RAS-/TP53-Mutant Metastatic Colorectal Cancer Reduced Risk of Progression, Death
September 21, 2021

Adavosertib demonstrated a 65% risk reduction in disease progression and death for patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Promising Preliminary Data for KRAS G12C Inhibition With Adagrasib Are Presented for CRC
September 19, 2021

Data from the KRYSTAL-1 trial show promise of adagrasib as monotherapy and in combination with other standard agents for colorectal cancer.

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform
September 15, 2021

Patients with colorectal cancer could benefit from the COLMATE platform as it allows for opportunities in clinical trial enrollment.

Onvansertib Plus Standard-of Care-Chemotherapy Meet Primary End Point of ORR in Metastatic Colorectal Cancer
September 09, 2021

The use of onvansertib in combination with standard-of-care chemotherapy had an increase in the objective response rate and progression-free survival during the phase 1b/2 trial for metastatic colorectal cancer.